<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02754154</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-433</org_study_id>
    <nct_id>NCT02754154</nct_id>
  </id_info>
  <brief_title>Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants</brief_title>
  <official_title>Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the risk of major bleeding event among nonvalvular
      atrial fibrillation patients treated with warfarin, apixaban, dabigatran and rivaroxaban.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 31, 2014</start_date>
  <completion_date type="Anticipated">February 26, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 26, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to &quot;First Major&quot; Bleeding event</measure>
    <time_frame>Up to 25 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to &quot;First Any&quot; Bleeding event</measure>
    <time_frame>Up to 25 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding-Related Healthcare Utilization</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>(Number of Hospitalizations, Total Length of Hospital Stay (days), Time to Hospitalization, Number Of Emergency Room (ER) visits, and Number of Outpatient Visits with at least 1 major bleeding event )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Bleeding-Related Healthcare Utilization</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>(Number of Hospitalizations, Total Length of Hospital Stay (days), Time to Hospitalization, Number Of Emergency Room (ER) visits, and Number of Outpatient Visits with at least 1 bleeding event )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding-Related direct medical cost</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>(Inpatient costs, Outpatient costs, and Emergency Room (ER) costs related to at least 1 major bleeding event)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Bleeding-Related direct medical cost</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>(Inpatient costs, Outpatient costs, and Emergency Room (ER) costs related to at least 1 bleeding event)</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">88983</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Patients using Warfarin</arm_group_label>
    <description>Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Warfarin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients using Apixaban</arm_group_label>
    <description>Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Apixaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients using Dabigatran</arm_group_label>
    <description>Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Dabigatran</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients using Rivaroxaban</arm_group_label>
    <description>Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Rivaroxaban</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <arm_group_label>Patients using Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <arm_group_label>Patients using Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <arm_group_label>Patients using Dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <arm_group_label>Patients using Rivaroxaban</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using oral
        anticoagulants
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients â‰¥18 years old as of the index date

          -  At least 1 diagnosis of atrial fibrillation in the 12 months prior to or on index
             date, identified by any medical claim

          -  At least one year of baseline period and continuous enrollment for at least 12 months
             prior to index date Individuals with NVAF who were using oral anticoagulants (i.e.,
             warfarin, dabigatran, rivaroxaban and apixaban) within the study period beginning Jan
             1, 2012 through December 31, 2013 or last date of the last data cut available at the
             time of execution of the study

        Exclusion Criteria:

          -  Patients with evidence of valvular heart disease, thyrotoxicosis, pericarditis, mitral
             stenosis, Venous thromboembolism(VTE), heart surgery, and endocarditis during the
             baseline period any time prior to or on index date

          -  Patients with any evidence of pregnancy at any time during the baseline will be
             excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

